Stock listing
NASDAQ:ZURA Zura Bio Limited Stock
Home listing (NASDAQ) of Zura Bio Limited
Follow Zura Bio Limited into a list and get an email when it puts out news.
Share price · NASDAQ:ZURA
$0.931 USD -0.035 (-3.6%)
Close on Nov 20, 2026
- Day range
- $0.919 – $1.001 USDNov 20, 2026
- Volume
- 4.76M sharesNov 20, 2026
- Market cap
- $89.63M USDAt the close on Nov 20, 2026 · price × 96.33M shares outstanding
- 52-week range
- $0.919 – $7.440 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $13.96M USDMedian day 2.65M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ZURA · Home | $0.931 USD | -0.035 (-3.6%) | 4,756,900 | $0.940 | $1.001 | $0.919 | $0.965 | Close on Nov 20, 2026 |
| Frankfurt:94E | €0.845 EUR | -0.060 (-6.6%) | — | €0.845 | €0.845 | €0.845 | €0.905 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ZURA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.931 | -0.035 | -3.6% | $0.940 | $1.001 | $0.919 | 4,756,900 | |
| $0.965 | -0.070 | -6.8% | $1.010 | $1.045 | $0.945 | 3,023,431 | |
| $1.035 | -0.045 | -4.2% | $1.050 | $1.070 | $0.983 | 3,521,789 | |
| $1.080 | -0.160 | -12.9% | $1.240 | $1.250 | $1.050 | 3,734,049 | |
| $1.240 | 0.000 | 0.0% | $1.230 | $1.250 | $1.130 | 4,239,089 | |
| $1.240 | -0.190 | -13.3% | $1.410 | $1.440 | $1.210 | 3,522,988 | |
| $1.430 | +0.025 | +1.8% | $1.405 | $1.575 | $1.350 | 6,940,510 | |
| $1.405 | +0.165 | +13.3% | $1.170 | $1.530 | $1.163 | 16,982,987 | |
| $1.240 | -2.850 | -69.7% | $1.270 | $1.270 | $0.934 | 64,340,588 | |
| $4.090 | +0.370 | +9.9% | $3.800 | $4.245 | $3.760 | 3,002,600 | |
| $3.720 | -0.300 | -7.5% | $4.000 | $4.010 | $3.700 | 2,655,000 | |
| $4.020 | +0.030 | +0.8% | $4.120 | $4.200 | $3.832 | 1,947,400 | |
| $3.990 | +0.050 | +1.3% | $3.990 | $4.130 | $3.900 | 1,930,200 | |
| $3.940 | -0.100 | -2.5% | $4.040 | $4.140 | $3.865 | 3,721,900 | |
| $4.040 | +0.190 | +4.9% | $3.810 | $4.060 | $3.655 | 4,074,200 | |
| $3.850 | -0.500 | -11.5% | $4.350 | $4.490 | $3.800 | 3,354,900 | |
| $4.350 | +0.080 | +1.9% | $4.230 | $4.600 | $4.110 | 4,389,400 | |
| $4.270 | +0.710 | +19.9% | $3.570 | $4.330 | $3.412 | 5,089,300 | |
| $3.560 | +0.200 | +6.0% | $3.350 | $3.800 | $3.345 | 4,294,900 | |
| $3.360 | -0.170 | -4.8% | $3.540 | $3.595 | $3.270 | 5,820,000 | |
| $3.530 | -0.600 | -14.5% | $4.380 | $4.470 | $3.500 | 8,812,100 | |
| $4.130 | +0.130 | +3.2% | $4.050 | $4.235 | $3.960 | 4,187,900 | |
| $4.000 | +0.190 | +5.0% | $3.830 | $4.210 | $3.810 | 3,317,600 | |
| $3.810 | -0.070 | -1.8% | $3.910 | $4.060 | $3.770 | 4,557,200 | |
| $3.880 | -0.400 | -9.3% | $4.300 | $4.350 | $3.860 | 4,899,700 | |
| $4.280 | -0.130 | -2.9% | $4.420 | $4.500 | $4.150 | 4,991,700 | |
| $4.410 | +0.180 | +4.3% | $4.230 | $4.615 | $4.170 | 5,748,900 | |
| $4.230 | +0.230 | +5.8% | $3.950 | $4.780 | $3.850 | 24,435,300 | |
| $4.000 | 0.000 | 0.0% | $4.000 | $4.120 | $3.945 | 1,606,900 | |
| $4.000 | -0.130 | -3.1% | $4.130 | $4.350 | $4.000 | 1,706,900 | |
| $4.130 | -0.040 | -1.0% | $4.120 | $4.160 | $3.905 | 2,696,100 | |
| $4.170 | +0.210 | +5.3% | $3.960 | $4.350 | $3.900 | 2,084,600 | |
| $3.960 | +0.030 | +0.8% | $3.970 | $4.055 | $3.820 | 1,427,200 | |
| $3.930 | -0.180 | -4.4% | $4.110 | $4.190 | $3.920 | 2,649,400 | |
| $4.110 | -0.030 | -0.7% | $4.210 | $4.360 | $4.075 | 2,953,800 | |
| $4.140 | -0.020 | -0.5% | $4.130 | $4.245 | $4.000 | 2,913,200 | |
| $4.160 | +0.160 | +4.0% | $4.040 | $4.230 | $3.980 | 3,325,600 | |
| $4.000 | -0.100 | -2.4% | $4.100 | $4.190 | $3.923 | 2,044,000 | |
| $4.100 | +0.060 | +1.5% | $4.030 | $4.190 | $3.920 | 1,465,000 | |
| $4.040 | -0.120 | -2.9% | $4.270 | $4.280 | $3.915 | 1,510,900 | |
| $4.160 | -0.170 | -3.9% | $4.320 | $4.320 | $3.840 | 3,433,200 | |
| $4.330 | -0.180 | -4.0% | $4.525 | $4.550 | $4.162 | 2,061,600 | |
| $4.510 | +0.010 | +0.2% | $4.560 | $4.620 | $4.450 | 2,150,200 | |
| $4.500 | +0.040 | +0.9% | $4.550 | $4.550 | $4.370 | 1,111,100 | |
| $4.460 | -0.110 | -2.4% | $4.500 | $4.608 | $4.400 | 1,657,100 | |
| $4.570 | -0.040 | -0.9% | $4.720 | $4.840 | $4.530 | 1,666,600 | |
| $4.610 | -0.320 | -6.5% | $4.940 | $4.980 | $4.584 | 1,269,700 | |
| $4.930 | -0.280 | -5.4% | $5.200 | $5.240 | $4.740 | 2,637,400 | |
| $5.210 | 0.000 | 0.0% | $5.210 | $5.360 | $5.150 | 1,039,100 | |
| $5.210 | -0.170 | -3.2% | $5.480 | $5.580 | $5.150 | 1,421,200 | |
| $5.380 | -0.330 | -5.8% | $5.600 | $5.740 | $5.365 | 1,150,900 | |
| $5.710 | -0.420 | -6.9% | $6.040 | $6.050 | $5.630 | 1,730,800 | |
| $6.130 | -0.100 | -1.6% | $6.230 | $6.230 | $5.900 | 1,617,100 | |
| $6.230 | +0.350 | +6.0% | $5.800 | $6.260 | $5.630 | 1,388,400 | |
| $5.880 | +0.210 | +3.7% | $5.690 | $5.940 | $5.500 | 1,773,100 | |
| $5.670 | +0.020 | +0.4% | $5.670 | $5.870 | $5.485 | 934,500 | |
| $5.650 | +0.110 | +2.0% | $5.520 | $5.680 | $5.390 | 1,096,200 | |
| $5.540 | -0.180 | -3.1% | $5.680 | $5.680 | $5.390 | 1,378,600 | |
| $5.720 | -0.130 | -2.2% | $5.880 | $5.890 | $5.490 | 1,892,700 | |
| $5.850 | -0.140 | -2.3% | $6.020 | $6.030 | $5.840 | 1,099,000 | |
| $5.990 | -0.330 | -5.2% | $6.130 | $6.300 | $5.980 | 1,794,500 | |
| $6.320 | +0.020 | +0.3% | $6.370 | $6.490 | $6.180 | 2,817,000 | |
| $6.300 | +0.450 | +7.7% | $5.850 | $7.060 | $5.619 | 8,341,800 | |
| $5.850 | +0.100 | +1.7% | $5.780 | $5.988 | $5.755 | 722,100 | |
| $5.750 | -0.090 | -1.5% | $5.810 | $5.810 | $5.540 | 796,900 |
- Ticker
- NASDAQ:ZURA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
Latest deck · Oct 27, 2026
Investor Presentation (October 2026)
Investor deck · 51 slides
Latest news
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
Nov 9, 2026
Closed $1.24 (-69.7%) on Nov 9, 2026
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 27, 2026
Closed $4.35 (+1.9%) on Oct 28, 2026
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Oct 27, 2026
Closed $4.27 (+19.9%) on Oct 27, 2026
Zura Bio to Participate in the Cantor Global Healthcare Conference
Aug 31, 2026
Closed $5.65 (+2.0%) on Sep 1, 2026
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Aug 11, 2026
Closed $5.56 (-1.2%) on Aug 11, 2026
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Jun 29, 2026
Closed $5.63 (+5.2%) on Jun 29, 2026
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
May 13, 2026
Closed $4.80 (+1.1%) on May 13, 2026
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
May 7, 2026
Closed $4.54 (-7.2%) on May 7, 2026
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Mar 19, 2026
Closed $6.12 (+2.2%) on Mar 19, 2026
Zura Bio Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 54 in all · newest Nov 9, 2026 · oldest 2023
- Decks
- 23 decks · latest Oct 27, 2026
Where Zura Bio Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ZURA · Home listing · This page | NASDAQ | United States | USD |
| Frankfurt:94E | Frankfurt | Germany | EUR |
| Stuttgart:94E | Stuttgart | Germany | EUR |
| BOATS:ZURA | BOATS | United States | USD |
| Dusseldorf:94E | Dusseldorf | Germany | EUR |
| Tradegate:94E | Tradegate | Germany | EUR |
Valuation
Price/book 0.5× against a median of 2.3×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$98.02M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.52
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Zura Bio Limited · NASDAQ:ZURA | US$89.63M | −US$98.02M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.52 |
| Brii Biosciences Limited · HKEX:2137 | US$91.58M | −US$173.2M | n/a | −63.7× | n/a | 0.3× | n/a | 0.0× | n/a |
| TWi Biotechnology, Inc · TPEX:6610 | US$91.56M | US$88.17M | n/a | n/a | n/a | 6.3× | n/a | 0.0× | n/a |
| NeOnc Technologies Holdings, Inc. · NASDAQ:NTHI | US$90.88M | US$85.02M | n/a | n/a | n/a | n/a | n/a | n/a | 1.44 |
| Infant Bacterial Therapeutics AB Class B · OMXSTO:IBT_B | US$88.47M | US$77.84M | n/a | n/a | n/a | 17.0× | n/a | 0.0× | n/a |
| Bio Solution Co., Ltd. · KRX:086820 | US$88.38M | US$79.74M | 137× | 6.2× | n/a | 2.9× | 5.0% | 0.0× | n/a |
| Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX | US$87.57M | US$11.59M | 1.3× | 0.5× | n/a | 1.2× | 273.7% | 0.1× | 0.72 |
| Retension Pharmaceuticals, Inc. · NASDAQ:RTSN | US$87.57M | US$78.38M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Y-Biologics Inc. · KRX:338840 | US$87.56M | US$70.92M | n/a | 30.1× | n/a | 6.8× | n/a | 0.9× | n/a |
| Equillium, Inc. · NASDAQ:EQ | US$87.26M | US$34.71M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.31 |
| Upstream Bio, Inc. · NASDAQ:UPB | US$87.15M | −US$119.4M | n/a | −41.6× | n/a | 0.4× | n/a | 0.0× | 1.95 |
| Median of the others | US$87.98M | US$74.38M | 69.1× | 0.5× | 2.3× | 139.4% | 0.0× | 1.38 |
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.79 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sandeep Kulkarni | Co-Founder, Chief Executive Officer and Director |
| Muzammil Mustufa | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Amit Munshi | Chairman |
| Ajay Nirula | Director |
| Dan Becker | Director |
| Jennifer Jarrett | Director |
| Mark Eisner | Director |
| Parvinder Thiara | Director |
| Sandeep Kulkarni | Co-Founder, Chief Executive Officer and Director |
| Steve Schoch | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 27, 2026 · Before open | +19.9% |
| Q2 2026 | Aug 11, 2026 · Before open | −1.2% |
| Q1 2026 | May 7, 2026 · Before open | −7.2% |
| Q4 2025 | Mar 20, 2026 | −9.0% |
| Q3 2025 | Nov 13, 2025 · Before open | −9.7% |
| Q2 2025 | Aug 14, 2025 · Before open | +8.2% |
| Q1 2025 | May 8, 2025 · Before open | +2.4% |
| Q4 2024 | Mar 25, 2025 | −1.1% |
| Q3 2024 | Nov 7, 2024 · Before open | +4.0% |
| Q2 2024 | Aug 13, 2024 · Before open | −2.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −2.3% |
| Q4 2023 | Mar 28, 2024 · Before open | +10.8% |
| Q3 2023 | Nov 13, 2023 · Before open | −6.5% |
| Q2 2023 | Aug 14, 2023 · Before open | +0.3% |
| Q1 2023 | May 31, 2023 | +15.1% |
| Q4 2022 | Mar 28, 2023 | −1.8% |
| Q3 2022 | Nov 14, 2022 | |
| Q2 2022 | Aug 12, 2022 | |
| Q1 2022 | Apr 11, 2022 | |
| Q3 2021 | Nov 19, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 51 slides | Oct 27, 2026 |
| Investor Presentation (August 2026) | Investor deck | 50 slides | Aug 11, 2026 |
| Investor Presentation (August 2026) | Investor deck | 51 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 31 slides | Jul 1, 2026 |
| Investor Presentation (May 2026) | Investor deck | 31 slides | May 7, 2026 |
| Investor Presentation (March 2026) | Investor deck | 31 slides | Mar 19, 2026 |
| Investor Presentation (March 2026) | Investor deck | 29 slides | Mar 10, 2026 |
| Investor Presentation (February 2026) | Investor deck | 29 slides | Feb 11, 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | Jan 12, 2026 |
| Investor Presentation (September 2025) | Investor deck | 25 slides | Sep 4, 2025 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Jefferies Global Healthcare Conference 2025 | Conference | 21 slides | Jun 4, 2025 |
| Investor Presentation (March 2025) | Investor deck | 39 slides | Mar 25, 2025 |
| Investor Presentation (January 2025) | Investor deck | 39 slides | Jan 13, 2025 |
| Investor Presentation (September 2024) | Investor deck | 48 slides | Sep 9, 2024 |
| Investor Presentation (August 2024) | Investor deck | 37 slides | Aug 14, 2024 |
| Investor Presentation (April 2024) | Investor deck | 32 slides | Apr 23, 2024 |
| Investor Presentation (March 2024) | Investor deck | 22 slides | Mar 11, 2024 |
| 42nd Annual J.P. Morgan Healthcare Conference (January 2024) | Conference | 19 slides | Jan 11, 2024 |
| Investor Presentation (October 2023) | Investor deck | 34 slides | Oct 25, 2023 |
| Investor Presentation (July 2023) | Investor deck | 31 slides | Jul 27, 2023 |
| Investor Presentation (June 2023) | Investor deck | 53 slides | Jun 15, 2023 |
| Investor Presentation (April 2023) | Investor deck | 54 slides | Apr 27, 2023 |
| SPAC Merger (June 2022) | SPAC merger | 30 slides | Jun 17, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of class A ordinary shares and pre-funded warrants Closed: US$144M raised · US$6.25 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Cantor (co-lead), Wedbush PacGrow | Feb 27, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as JATT Acquisition Corp, a blank check company (SPAC). Priced at US$10.00 a unit on Jul 13, 2021.
- Price
- US$10.00 a unit
- Units offered
- 12,000,000 units
- Offering size
- US$120 million
- Underwriters' option
- Up to 1,800,000 more units
- Listing
- JATT U on the New York Stock Exchange
- Underwriter
- Raymond James
- Units delivered
- On or about Jul 16, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 8, 2021 |
| Filed publicly | Jun 15, 2021 |
| Amended once | Jul 6, 2021 |
| Shares registered with an exchange | Jul 13, 2021 |
| Declared effective by the SEC | Jul 13, 2021 |
| Final prospectus, with the price | Jul 14, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 14, 2021 |
| EFFECT · Notice that a registration is effective | Jul 13, 2021 |
| CERT · Exchange's certificate of listing | Jul 13, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 8, 2021 |
| CORRESP · Letter to the SEC | Jul 8, 2021 |
| S-1/A · Registration statement, amended | Jul 6, 2021 |
| CORRESP · Letter to the SEC | Jun 15, 2021 |
| S-1 · Registration statement | Jun 15, 2021 |
| UPLOAD · Letter from the SEC | May 5, 2021 |
All 11 filings
| Filing | Filed |
|---|---|
| DRS · Draft registration statement | Apr 8, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 14, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 42.1M | 24.4M | 44.0M | |
| Operating income | -75.2M | -55.2M | -62.6M | -2.68M |
| Depreciation and amortization | 49.0K | 9.00K | ||
| EBITDA | -75.2M | -55.2M | ||
| Income before tax | -68.7M | -52.4M | -60.6M | |
| Income tax | 0 | 0 | ||
| Net income | -68.7M | -52.4M | -60.4M | -25.7M |
| Earnings per share, basic | -1.06 | -0.60 | -2.09 | -91.88 |
| Earnings per share, diluted | -1.06 | -0.60 | -2.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 109.4M | 176.5M | 99.8M | 13.8K |
| Current assets | 112.3M | 178.7M | 100.8M | 1.78M |
| Property, plant and equipment | 126.0K | 91.0K | ||
| Total assets | 113.9M | 179.5M | 100.8M | 5.26M |
| Accounts payable | 1.28M | 733.0K | 2.75M | 2.01M |
| Current liabilities | 12.4M | 19.5M | 20.3M | 14.8M |
| Total liabilities | 12.4M | 19.5M | 21.3M | 14.8M |
| Shareholders' equity | 101.5M | 146.8M | 59.3M | -32.1M |
| Shares outstanding | 73.7M | 65.3M | 43.6M | 279.7K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -64.8M | -28.1M | -15.1M | -1.07M |
| Capital spending | -113.0K | -75.0K | ||
| Free cash flow | -64.9M | -28.2M | ||
| Cash from investing | -113.0K | -5.08M | -8.00M | |
| Cash from financing | -2.16M | 109.8M | 121.3M | 355.6K |
| Change in cash | -67.1M | 76.7M | 98.2M | -715.4K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 4, 2026 | Other filings | SEC |
| S-3 · Registration statement | Oct 27, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 27, 2026 | Results | SEC |
| 10-Q · Quarterly report | Oct 27, 2026 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Sep 30, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 17, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Management or board change | SEC |
| DEFA14A · Additional proxy material | May 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 22, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 23, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| 8-K · Current report | Mar 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 2, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Feb 26, 2026 | Current report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| 424B5 · Prospectus | Feb 25, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 24, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Feb 24, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 23, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 27, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 23, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 2, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2026 | Material contract | SEC |
| 8-K · Current report | Dec 17, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Oct 10, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 30, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jun 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 29, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | May 28, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 28, 2025 | Insider trade | SEC |
| 8-K · Current report | May 27, 2025 | Current report | SEC |
| 8-K · Current report | May 23, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | May 22, 2025 | Other filings | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 8, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 17, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 8-K · Current report | Oct 30, 2024 | Current report | SEC |
| 8-K · Current report | Oct 29, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Oct 18, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 23, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Sep 18, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 16, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Sep 16, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Sep 13, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Sep 13, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 13, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| S-3/A · Registration statement, amended | Sep 11, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 11, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 11, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 10, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 9, 2024 | Current report | SEC |
| 4/A · Change in ownership, amended | Sep 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 6, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 6, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 6, 2024 | Insider trade | SEC |
| POS AM · Amendment to an effective registration | Sep 5, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Sep 5, 2024 | Offer document | SEC |
| 144 · Notice of proposed sale | Sep 4, 2024 | Other filings | SEC |
| S-3 · Registration statement | Sep 3, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 25-NSE | Aug 27, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 21, 2024 | Material contract | SEC |
| 8-K · Current report | Aug 14, 2024 | Current report | SEC |
| 424B3 · Prospectus | Aug 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 425 | Aug 12, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 12, 2024 | Material contract | SEC |
| SC TO-I/A | Aug 9, 2024 | Acquisition or disposal | SEC |
| 425 | Aug 9, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 9, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 9, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Aug 8, 2024 | Offer document | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 25, 2024 | Other filings | SEC |
| SC TO-I/A | Jul 25, 2024 | Acquisition or disposal | SEC |
| S-4/A · Registration statement, amended | Jul 25, 2024 | Offer document | SEC |
| 425 | Jul 25, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 25, 2024 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Jul 19, 2024 | Other filings | SEC |
| 425 | Jul 12, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 12, 2024 | Current report | SEC |
| SC TO-I | Jul 12, 2024 | Acquisition or disposal | SEC |
| S-4 · Registration statement | Jul 11, 2024 | Offer document | SEC |
| 8-K/A · Current report, amended | Jul 2, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
This page holds 200 of 447 filings. Open Filings
Cap table
Built by 6ix from Zura Bio Limited’s releases · as of Feb 27, 2026
- Common shares
- 96,325,411
- Fully diluted
- 96,325,411
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 96,325,411 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 96,325,411 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jennifer Jarrett Other companies: Damora Therapeutics, Inc. (President and Chief Executive Officer in March 2026, Board Director · Since at least Mar 30, 2026); Sagimet Biosciences Inc. - Series A (Board Member · Since at least Aug 1, 2024); Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 25, 2018); Arcus Biosciences, Inc. (Chief Operating Officer · Since at least Mar 14, 2018); Radius Health, Inc. (Director · May 18, 2022 – Aug 15, 2022 · Past); Surrozen, Inc. (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Arena Pharmaceuticals Inc (Director · Jun 13, 2017 – Mar 11, 2022 · Past); Audentes Therapeutics Inc (Director · Jun 12, 2017 – Jan 15, 2020 · Past); Medivation Inc (Chief Financial Officer · Apr 7, 2016 – Sep 28, 2016 · Past) | Director · Since at least Mar 20, 2023 |
| Amit Munshi Other companies: Arcutis Biotherapeutics, Inc. (Director · Since at least Dec 4, 2025); Inhibikase Therapeutics, Inc. (Board of Directors Chair, Inhibikase; Chief Executive Officer of Orna Therapeutics · Since at least Oct 21, 2024); Damora Therapeutics, Inc. (Director · Since at least Oct 28, 2020); Social Capital Suvretta Holdings Corp IV (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Pulmatrix, Inc. (Director · Jun 13, 2017 – Jan 28, 2021 · Past); Arena Pharmaceuticals Inc (President and CEO, Director · May 11, 2016 – Mar 11, 2022 · Past); EPIRUS Biopharmaceuticals Inc (Chief Executive Officer, Director · Jul 15, 2014 – Feb 27, 2016 · Past) | Chairman · Since at least Mar 20, 2023 |
| Preston Klassen Other companies: Regulus Therapeutics Inc (President & Head of R & D, Director · Since at least Jun 12, 2023); Metacrine Inc (Director · Sep 15, 2020 – Mar 23, 2023 · Past); Arena Pharmaceuticals Inc (EVP and CMO · Mar 20, 2017 – Mar 1, 2020 · Past); Histogen Inc (Director · Feb 7, 2014 – Jun 27, 2019 · Past); Orexigen Therapeutics Inc (EVP, Global Development · May 27, 2010 – Feb 2, 2016 · Past) | President and COO · Mar 20, 2023 – Mar 20, 2023 · Past |
| Dan Becker Other companies: Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Day One Biopharmaceuticals Inc (Director · May 26, 2021 – Jun 22, 2023 · Past); Pandion Therapeutics Inc (Director · Jul 16, 2020 – Apr 1, 2021 · Past); Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 28, 2020 · Past) | Director · Since at least May 21, 2025 |
| Christopher Cabell Other companies: Inhibikase Therapeutics, Inc. (President & Head of R&D · Since at least Feb 21, 2025); Pulmatrix, Inc. (Director · Jun 23, 2020 – Jan 26, 2023 · Past); Arena Pharmaceuticals Inc (EVP, Head of R&D, and CMO · Jun 2, 2020 – Nov 25, 2020 · Past) | CMO & Head of R&D · Mar 20, 2023 – May 18, 2023 · Past |
| Robert Lisicki Other companies: Arcutis Biotherapeutics, Inc. (Chief Commercial Officer · Since at least Nov 5, 2026); Cadrenal Therapeutics, Inc. (Director · Jul 23, 2023 – Jan 23, 2025 · Past); Arena Pharmaceuticals Inc (EVP, Chief Commercial Officer · Aug 4, 2020 – Mar 11, 2022 · Past) | Chief Executive Officer, Director · Jan 8, 2024 – Feb 27, 2025 · Past |
| Eric Hyllengren Other companies: Tenaya Therapeutics, Inc. (Chief Financial Officer · Since at least Jun 29, 2026); Atara Biotherapeutics, Inc. (EVP, CFO and COO · Apr 1, 2023 – Mar 3, 2025 · Past) | Chief Financial Officer · Since at least Jul 1, 2025 |
| Mark Eisner Other companies: Jade Biosciences, Inc. (Director · Since at least Jun 25, 2026); Vir Biotechnology, Inc. (EVP and Chief Medical Officer · Since at least Jun 3, 2024) | Director · Since at least Feb 21, 2026 |
| Sandeep Kulkarni Other companies: Amanat Acquisition Corp (Director and Chairman, Director · Since at least May 18, 2026); Tourmaline Bio Inc. (CEO, Director · Since at least Oct 19, 2023) | Co-Founder, Chief Executive Officer and Director · Since at least Mar 20, 2023 |
| Someit Sidhu Other companies: JATT III Acquisition Corp (CEO and Chairman, Director · Since at least Aug 25, 2026); JATT II Acquisition Corp (Chief Executive Officer, Director · Since at least Apr 16, 2026) | Director · Jul 13, 2021 – May 21, 2025 · Past |
All 26 people
| Person | Seat |
|---|---|
| Steve Schoch Other companies: 23Andme Holding Co (Chief Financial Officer · Jun 16, 2021 – Aug 20, 2022 · Past); Arena Pharmaceuticals Inc (Director · Jun 11, 2021 – Mar 11, 2022 · Past) | Director · Since at least Mar 20, 2023 |
| Verender S Badial Other companies: JATT III Acquisition Corp (Director · Since at least Aug 25, 2026); JATT II Acquisition Corp (Director · Since at least Apr 16, 2026) | Chief Financial Officer · Jul 13, 2021 – May 8, 2025 · Past |
| Neil Murray Hamilton Graham Other companies: Allakos Inc (Director · Aug 25, 2023 – May 15, 2025 · Past) | Director · Mar 20, 2023 – May 21, 2025 · Past |
| Parvinder Thiara Other companies: Tourmaline Bio Inc. (Director · Since at least Oct 19, 2023) | Director · Since at least Jun 22, 2023 |
| Ajay Nirula | Director · Since at least Feb 21, 2026 |
| Gary Whale | Chief Technology Officer · Since at least Mar 20, 2023 |
| Javier Cote-Sierra | Director · Jul 13, 2021 – Jul 13, 2021 · Past |
| Josh Distler | Director · Jul 13, 2021 – Jul 13, 2021 · Past |
| Kim Davis | Chief Legal Officer · Since at least Mar 20, 2023 |
| Kiran Nistala | See Remarks · Since at least Nov 30, 2023 |
| Marlyn Teresa Mathew | VP, Principal Acctg. Officer · Since at least Apr 17, 2026 |
| Michael Howell | See Remarks · Mar 20, 2023 – Jun 18, 2024 · Past |
| Mir Tauhid Ali | Chief Operating Officer, Director · Jul 13, 2021 – Jul 13, 2021 · Past |
| Muzammil Mustufa | Chief Business Officer · Since at least May 13, 2026 |
| Theresa Lowry | EVP and CHRO · Mar 20, 2023 – Mar 20, 2023 · Past |
| van Amstel Arnout Ploos | Director · Jul 13, 2021 – May 21, 2025 · Past |
Log in to ask 6ix AI your own questions about Zura Bio Limited.